drugset
drugset / Trial / NCT04294147

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

NCT04294147 ↗

Phase 4 Completed 65 enrolled Eli Lilly and Company
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab.

Timeline

Start
2020-10-06
Primary completion
2021-03-05
Completion
2021-03-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Erenumab Monoclonal antibody 140 mg Subcutaneous
Subject Galcanezumab Monoclonal antibody 240 mg Subcutaneous

Indications

migraine disorder